CN115151260A - 氟维司群前药 - Google Patents

氟维司群前药 Download PDF

Info

Publication number
CN115151260A
CN115151260A CN202080093658.5A CN202080093658A CN115151260A CN 115151260 A CN115151260 A CN 115151260A CN 202080093658 A CN202080093658 A CN 202080093658A CN 115151260 A CN115151260 A CN 115151260A
Authority
CN
China
Prior art keywords
group
optionally substituted
aryl
heteroaryl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080093658.5A
Other languages
English (en)
Chinese (zh)
Inventor
帕瓦·约格什钱德拉·普罗希特
帕斯克·苏巴什钱德拉·布拉姆沙特里亚
维沙尔吉里·冈万吉里·戈斯瓦米
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kashif Bioscience Co ltd
Original Assignee
Kashif Bioscience Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kashif Bioscience Co ltd filed Critical Kashif Bioscience Co ltd
Publication of CN115151260A publication Critical patent/CN115151260A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/006—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton spiro-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202080093658.5A 2019-11-24 2020-11-24 氟维司群前药 Pending CN115151260A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN201921047986 2019-11-24
IN201921047986 2019-11-24
IN202021029084 2020-07-08
IN202021029084 2020-07-08
PCT/IB2020/061065 WO2021100029A2 (en) 2019-11-24 2020-11-24 Prodrugs of fulvestrant

Publications (1)

Publication Number Publication Date
CN115151260A true CN115151260A (zh) 2022-10-04

Family

ID=75980095

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080093658.5A Pending CN115151260A (zh) 2019-11-24 2020-11-24 氟维司群前药

Country Status (7)

Country Link
US (1) US20230137764A1 (https=)
EP (1) EP4061376A4 (https=)
JP (2) JP2023503898A (https=)
CN (1) CN115151260A (https=)
AU (1) AU2020386864A1 (https=)
CA (1) CA3162182A1 (https=)
WO (1) WO2021100029A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4422636A4 (en) * 2021-10-29 2025-09-03 Kashiv Biosciences Llc INECTABLE PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF BREAST CANCER
WO2023103929A1 (zh) * 2021-12-06 2023-06-15 江苏亚虹医药科技股份有限公司 氟维司群衍生物及其制备方法和医药用途
EP4444318A4 (en) * 2021-12-06 2026-01-28 Amneal Pharmaceuticals Llc COMPOUNDS FOR CANCER TREATMENT
CN114716496B (zh) * 2022-04-29 2024-04-02 香港中文大学（深圳） 氟维司群衍生物及氟维司群衍生物制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103421069A (zh) * 2013-05-23 2013-12-04 中国海洋大学 氟维司群磷酸酯衍生物及其制备方法和应用
US20160060288A1 (en) * 2013-04-18 2016-03-03 Xi'anlibang Pharmaceutical Technology Co., Ltd. Ester derivatives of 7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-estra-1,3,5(10)-triene-3,17beta-diol having anticancer activity and preparation method thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2176208T3 (en) * 2007-07-30 2015-04-27 Zynerba Pharmaceuticals Inc Prodrugs of cannabidiol, compositions containing prodrugs of cannabidiol and methods of use thereof
US20140079636A1 (en) * 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
WO2014169456A1 (zh) * 2013-04-18 2014-10-23 西安力邦医药科技有限责任公司 7-α-[9-(4,4,5,5,5-五氟戊基亚硫酰基)壬基]-雌甾-1,3,5(10)-三烯-3,17β-二醇及其衍生物的用途
EP3738594A1 (en) * 2013-09-10 2020-11-18 Madrigal Pharmaceuticals, Inc. Targeted therapeutics having an hsp90 ligand as binding moiety
WO2019050850A1 (en) * 2017-09-05 2019-03-14 Primetime Life Sciences, Llc BIGUANIDINE DERIVATIVES OF THERAPEUTIC AGENTS, AND PREPARATION METHODS AND METHODS OF USING SAME
JP7384903B2 (ja) * 2018-05-24 2023-11-21 ケーアイ ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー フルベストラントのプロドラッグ

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160060288A1 (en) * 2013-04-18 2016-03-03 Xi'anlibang Pharmaceutical Technology Co., Ltd. Ester derivatives of 7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-estra-1,3,5(10)-triene-3,17beta-diol having anticancer activity and preparation method thereof
CN103421069A (zh) * 2013-05-23 2013-12-04 中国海洋大学 氟维司群磷酸酯衍生物及其制备方法和应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J.M. FÉRRIZ，等: "Prodrug Design of Phenolic Drugs", 《CURRENT PHARMACEUTICAL DESIGN》, vol. 16, pages 2033 - 2049 *

Also Published As

Publication number Publication date
WO2021100029A2 (en) 2021-05-27
EP4061376A2 (en) 2022-09-28
EP4061376A4 (en) 2024-03-13
US20230137764A1 (en) 2023-05-04
JP2023503898A (ja) 2023-02-01
AU2020386864A1 (en) 2022-06-16
CA3162182A1 (en) 2021-05-27
JP2026032104A (ja) 2026-02-25
WO2021100029A3 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
CN115151260A (zh) 氟维司群前药
JP7653092B2 (ja) フルベストラントのプロドラッグ
JP7759063B2 (ja) プロドラッグ化合物、その製造方法、及び用途
ES2628953T3 (es) Sulfamoilarilamidas y el uso de las mismas como medicamentos para el tratamiento de la hepatitis B
ES2693368T3 (es) Derivados de dolastatina 10 y auristatinas
JP2021527666A (ja) Ｗｄ４０反復ドメインタンパク質５（ｗｄｒ５）分解／破壊化合物および使用の方法
JP2022545542A (ja) ピラゾール化合物、その製剤並びに化合物及び／又は製剤を使用する方法
ES2626246T3 (es) Derivado de 8-oxodihidropurina
CN112714760A (zh) 依达拉奉前体药物化合物及其在治疗或改善神经退行性或运动神经元疾病中的医药用途
IL276852B1 (en) A process for making soluble guinelate cyclase beads
KR102961556B1 (ko) 프로드러그 화합물 및 이의 제조 방법과 용도
CA3024324C (en) Seco macrolide compounds
WO2024197317A2 (en) Neurosteroids and prodrugs thereof
TW200918065A (en) Imidazopyridazine derivatives
WO2026078657A1 (en) Prodrugs of riluzole
WO2026073221A1 (en) Glutamate carboxypeptidase ii inhibitor conjugates for inflammatory bowel disease
JP4813469B2 (ja) 置換されたプロパンホスフィン酸誘導体
WO2024130689A1 (zh) 2-氟联苯-4-乙酸衍生物及其制备方法与应用
WO2013013240A2 (en) Macrocyclic compounds and related compositons and methods of use
NZ615880A (en) Prodrugs of d-isoglutamyl-[d/l]-tryptophan

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination